

Enveric highlights EB-003 PTSD data as Trump-backed psychedelic research signals rising demand for new mental health treatments.
You can purchase shares of Enveric Biosciences (NASDAQ:ENVB) through any online brokerage.
Other companies in Enveric Biosciences’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Enveric Biosciences has a consensus price target of $120.00.
The stock price for Enveric Biosciences (NASDAQ: ENVB) is $1.42 last updated October 23, 2026 at 11:51 AM EDT.
There are no upcoming dividends for Enveric Biosciences.
Enveric Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Enveric Biosciences.
Enveric Biosciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003,...